A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- BIAsp 30
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Guwahati,Ahmedabad,Bangalore,Bangalore,Gulbarga,Mysore,Kolhapur,Nasik,Pune,Coimbatore,Coimbatore,Madurai,Lucknow,Lucknow,Kolkata,Belgaum,New Delhi,Thriruvananthapuram, India
- Phase
- N/A
- Start date
- Nov 13, 2017
- End date
- Jul 04, 2018
- Enrollment
- 516 participants
Proportion of patients who are using BIAsp 30 as their primary insulin
The purpose of this study is to collect information about the participant's ability and
 willingness to pay for NovoMix 30 using a modern device, which is prescribed to the
 participant by the study doctor for Type 2 Diabetes Mellitus according to routine clinical
 practice. The study aims to obtain data that can guide prescribers' understanding of the
 ability and willingness to pay for NovoMix 30 FlexPen or Penfill among participants in the
 growing middle class in India and Egypt. The decision to prescribe NovoMix 30 FlexPen or
 Penfill has been made independent from this study.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03374774
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03374774 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 516 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.